San Diego, CA (PRWEB) October 25, 2014
Triton Algae Innovations, a pioneer in synthetic biology, today announced Dr. Xun Wang has joined the firm as President and Director of all Research & Development.
Triton has developed a patented synthetic biology platform for the production of high value algae-based proteins. According to Dr. Wang, the platform uses algae to produce novel products with advantages over traditional expression systems. He says, “Algae are unique because they can produce compounds that other organisms cannot. What’s more, they can be safely consumed without modification. And, they can be cultivated inexpensively at large scale, a key component to commercialization.”
Triton’s products represent a paradigm shift in how proteins are developed and delivered, and satisfy a market that cannot be met by traditional methods. Triton produces complex proteins, enzymes, and other biologics that are cost- effective and have immediate applications in agricultural, pharmaceutical, and other retail markets.
Prior to Triton, Dr. Wang was a Senior Vice President at Reliance Industries Limited, a Fortune Global 500 company. As the Head of Technology, his responsibilities included overseeing all aspects of Algae-to-Oil technology development, driving company scientific strategy, and developing internal and external scientific collaborations. Previously, he was the Senior Vice President of R&D at Sapphire Energy Inc., a leading algae biofuel start-up company based in San Diego. Here, Dr. Wang led all R&D programs, including algae genetics and biotechnology, and cultivation and harvesting systems.
From 1993 to 2010, Dr. Wang held various positions in leading agricultural industries. Dr. Wang was the President of Syngenta Biotechnology (China) Co. Ltd. (SBC). He was also the Asia Pacific Regional Head of Biotechnology in Syngenta, a member in the Syngenta Global R&D Leadership Council, and a member of the Syngenta Global Biotechnology Leadership Team. From 2006 to 2010, he led the effort of setting up SBC, a Syngenta global R&D center. Before this, he was the Head of Trait Research and Technologies at the Syngenta global biotech R&D center in North Carolina, as well as the Founder and Director at Torrey Mesa Research Institute (Syngenta) in San Diego. Prior to Syngenta, Dr. Wang was a Research Manager in Pioneer Hi-Bred International, Iowa, a DuPont Company, where he led the very first genome project in the agricultural industry.
Dr. Wang is author or co-author of 52 patents and has published 21 international, peer-reviewed research articles. He holds a B.S. in Chemistry and an M.S. in Biochemistry from Jilin University, and a Ph.D. in Biochemistry and Biophysics from Iowa State University.
“We’re delighted that Dr. Wang has joined the Triton team,” said Dr. Jason Pyle, CEO of Triton. “He, Dr. Mayfield, and I worked together at Sapphire Energy and his leadership skills were evident from day one. Dr. Wang’s grounding in agricultural biotechnology makes him one of the foremost algae biotech experts in the world.”
Headquartered in San Diego, Triton Algae Innovations has created the world’s foremost algae platform for producing high value proteins and other biologics. The firm’s Phycologix technology will spur algae industry-wide to the forefront of protein production.
Proteins produced through the Psychololgix process will find wide application in pharmaceuticals, nutraceuticals, cosmetics, and human and animal health and nutrition products, such as antibacterials, vaccines, hormones, and antioxidants.
Triton’s Mammary Associated Amyloid (MAA), a mammalian colostrum protein that addresses intestinal diseases in pets, livestock, and humans, will be available commercially in limited quantities in early 2015. For more information, please visit Dr. W.E. Julien. Ph.D., D.V.M, Managing Director of Animal Health: wejulien(at)triton(dot)com
Daniel Sachs, Director of Business Development